- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, March 8, 2024
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Articles published by Medriva and BioSpace referenced a study published in the February 2024 issue of The American Journal of Managed Care® (AJMC®). The study, “Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications,” examined the clinical development landscape and potential impacts of the Inflation Reduction Act (IRA) of 2022 on high-spend Medicare Part D small molecule drugs, finding that longer development timelines and decreased investments in additional indications could reduce incentives for postapproval research.
An article from Myasthenia Gravis News referenced an article published on AJMC.com, the website of AJMC. The article, “Not So Rare: 300 Million People Worldwide Affected by Rare Diseases,” summarized a study that estimated that approximately 4% of the total world population is affected by a rare disease.
Articles from Medpage Today and Drug Topics® referenced an article published by AJMC’s sister site, The Center for Biosimilars®. The article, “FDA Approves First Denosumab Biosimilars,” reported on the FDA approvals for Sandoz’ Wyost and Jubbonti (both denosumab-bddz) to treat osteoporosis and prevent skeletal-related events associated with bone metastases from solid tumors. The biosimilars are the first approved products to reference originator denosumab (Prolia/Xgeva).
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Conflicts of Interest in Federal Vaccine Advisory Committees at Historic Lows Despite RFK Jr Claims
August 19th 2025Research reveals a significant decline in reported conflicts of interest among the CDC's and FDA's vaccine advisory committees, challenging Robert F. Kennedy Jr's claims.
Read More
